pharma · Advanced Solid Tumor · XLO
Xilio Therapeutics
Xilio Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker XLO. Primary therapeutic focus areas include Advanced Solid Tumor. NovaPharmaNews links 3 clinical program(s), 0 d
Waltham, USA HQ
2016 Founded
89 Employees
Public company Type
XLO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2016
- Employees
- 89
- Programs
- 3
- Drugs
- 0
- Patents
- 7
XTX301
Phase 2 · small molecule · Advanced Solid Tumor
XTX301 for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Xilio Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code XTX301-01/02-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xilio Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- active
- Trials
- 1